論文 - 詳細
| RRC ID | 85975 |
|---|---|
| 著者 | Xu Y, Yang JC, Zhao Y, Doucet L, Zhou J, Wang Y, Planchard D, Fan Y, Jin B, Han Z, Greillier L, Mazieres J, Sun M, Hu Y, Song X, Ding C, Wu L, Tang K, Liang L, Yao Y, Cheng Y, He Y, Ferreira BP, Ghiringhelli F, Felip E, Bosch-Barrera J, Liu A, Yu Y, Dong X, Gao J, Camidge DR, Nian W, Zhou C, Yang R, John T, Gao B, Bazhenova L, Nagasaka M, Wang J, Ren X, Xu F, Li W, Zhao D, Wang H, Sun S, Huang J, Zhu X, Zheng L, Jänne PA, Wang M. |
| タイトル | Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation. |
| ジャーナル | Cell Rep Med |
| Abstract |
This is a report of biomarker analysis for sunvozertinib, a leading epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeting EGFR exon 20 insertion mutation (exon20ins) non-small cell lung cancer (NSCLC). There is a positive correlation between positive EGFR exon20ins in plasma circulating tumor DNA (ctDNA) and advanced disease. Shorter progression-free survival and lower objective response rate (45.8% vs. 68.0%) were observed in patients with positive EGFR exon20ins compared to those with negative status. Droplet digital PCR analysis showed that the EGFR exon20ins allele in ctDNA decreased over time in 85.7% of patients, with the earliest clearance occurred after 1 week of sunvozertinib treatment. Acquired EGFR C797S is identified as a potential on-target resistance mutation to sunvozertinib. Finally, efforts are undertaken to investigate therapeutic approaches that aim to overcome the putative acquired resistance to sunvozertinib. |
| 巻・号 | 6(5) |
| ページ | 102121 |
| 公開日 | 2025-5-20 |
| DOI | 10.1016/j.xcrm.2025.102121 |
| PII | S2666-3791(25)00194-6 |
| PMID | 40334661 |
| PMC | PMC12147912 |
| MeSH | Aged Biomarkers, Tumor* / genetics Carcinoma, Non-Small-Cell Lung* / drug therapy Carcinoma, Non-Small-Cell Lung* / genetics Carcinoma, Non-Small-Cell Lung* / pathology Circulating Tumor DNA / blood Circulating Tumor DNA / genetics Drug Resistance, Neoplasm / genetics ErbB Receptors / genetics Exons / genetics Female Humans Lung Neoplasms* / drug therapy Lung Neoplasms* / genetics Male Middle Aged Mutagenesis, Insertional* / genetics Prognosis Protein Kinase Inhibitors / therapeutic use |
| リソース情報 | |
| ヒト・動物細胞 | Ba/F3(RCB0805) |